HSP90AA1 and lung adenocarcinoma: In the present work, an iTRAQ-based high-throughput quantitative proteomics technique was used to evaluate molecular context-dependent responses to different HSP90 inhibitors and to identify proteins that could potentially be used as biomarkers of the response to inhibition of this chaperone in lung adenocarcinoma.